OncoCyte Overview
Update this profile
Share Price
$0.98
(As of Thursday Closing)
OncoCyte General Information
Description
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnostics for the early detection of cancer. The company develops diagnostic tests based on liquid biopsies using blood or urine samples for detecting lung, bladder, and breast cancers. In addition, it also develops screening diagnostics as potential replacements for screening imaging procedures that do not meet the needs of patients, health care providers or payers. Geographically operation of the group is carried through the United States, and it earns revenue from the sale of diagnostic tests.
Contact Information
Want to dig into this profile?
We’ll help you find what you need
Learn more
OncoCyte Stock Performance
(As of Thursday Closing)
Stock Price
Previous Close
52 wk Range
Market Cap
Shares
Average Volume
EPS
$0.98
$0.95
$0.81 - $5.48
$119M
125M
474K
-$0.72
OncoCyte Financials Summary
In Thousands, USD
TTM
30-Jun-2022
FY 2021
31-Dec-2021
FY 2020
31-Dec-2020
FY 2019
31-Dec-2019
EV
90,761
162,105
158,526
109,684
Revenue
8,064
7,727
1,216
0
EBITDA
(63,182)
(68,944)
(30,540)
(22,374)
Net Income
(68,276)
(64,097)
(29,932)
(22,426)
Total Assets
171,051
159,563
55,419
39,859
Total Debt
4,547
5,677
8,632
5,936
Public Fundamental Data provided by Morningstar, Inc.
disclaimer
OncoCyte Valuation & Funding
Deal Type
Date
Amount
Valuation/ EBITDA
Post-Val
Status
Debt
This information is available in the PitchBook Platform. To explore OncoCyte‘s full profile, request access.
Request a free trial
OncoCyte Comparisons
Description
Primary Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
OncoCyte Corp focuses on the discovery, development, and commercialization of novel, non-invasive, liquid biopsy diagnos
Diagnostic Equipment
Irvine, CA
115
As of 2021
000.00
000000000
000.00
uis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commodo consequat. Duis aute irure do
0000000000000
San Diego, CA
000
As of 0000
00000
000000000
00000
abore et dolore magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nis
0000000000 000000000
Redwood City, CA
0000
As of 0000
00000
000000 - 000
00000
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trial
OncoCyte Competitors (34)
Company Name
Financing Status
Location
Employees
Total Raised
Last Financing Date/Type
Last Financing Amount
DermTech
Formerly VC-backed
San Diego, CA
000
00000
000000000
00000
00000000 000000
Formerly VC-backed
Redwood City, CA
0000
00000
000000 - 000
00000
0000000
Formerly VC-backed
Cambridge, United Kingdom
00
00000
000000&0
00000
000000000
Venture Capital-Backed
Siena, Italy
00
0000000000 0
00000000
Venture Capital-Backed
Seattle, WA
00
0000
00000000000
0000
You’re viewing 5 of 34 competitors. Get the full list »
OncoCyte Patents
14
Total Documents
Applications and Grants
000
Total Patents
Families
000
Granted
000
Pending
000
Expiring
in next 12 mo
OncoCyte Recent Patent Activity
Publication ID
Patent Title
Status
First Filing Date
Technology (CPC)
Citations
US-20130295581-A1
Methods and compositions for the treatment and diagnosis of breast cancer
Abandoned
04-May-2012
00000000000
0
US-20150018235-A1
Methods and compositions for the treatment and diagnosis of pancreatic cancer
Abandoned
13-Jan-2012
000000000000
US-20140357518-A1
Methods and compositions for the treatment and diagnosis of thyroid cancer
Abandoned
12-Jan-2012
0000000000
AU-2012203810-B2
Methods and compositions for the treatment and diagnosis of bladder cancer
Ceased
22-Jun-2011
0000000000
0
EP-2723898-A4
Methods and compositions for the treatment and diagnosis of bladder cancer
Withdrawn
22-Jun-2011
C12Q1/6886
0
To view OncoCyte’s complete patent history, request access »
OncoCyte Executive Team (12)
Update this profile
Name
Title
Board Seat
Contact Info
Ronald Andrews
Chief Executive Officer & Board Member
William Annett
Chief Executive Officer & Board Member
Mitchell Levine
Chief Financial Officer, Finance
Gisela Paulsen
Chief Operating Officer, Operations
Douglas Ross Ph.D
Chief Scientific Officer
You’re viewing 5 of 12 executive team members. Get the full list »
OncoCyte Board Members (9)
Name
Representing
Role
Since
Alfred Kingsley JD
Self
Board Member
000 0000
Andrew Arno
OncoCyte
Chairman & Board Member
000 0000
Andrew Last Ph.D
Self
Board Member
000 0000
Jennifer Carter MD
Self
Board Member
000 0000
Melinda Griffith JD
Self
Board Member
000 0000
You’re viewing 5 of 9 board members. Get the full list »
OncoCyte Signals
Growth Rate
0.80%
Weekly Growth
Weekly Growth
0.80%, 93rd %
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trial
OncoCyte Investors
Investor Name
Investor Type
Holding
Investor Since
Participating Rounds
Contact Info
This information is available in the PitchBook Platform. To explore OncoCyte‘s full profile, request access.
Request a free trial
OncoCyte
Investments & Acquisitions (5)
Company Name
Deal Date
Deal Type
Deal Size
Industry
Lead Partner
0000000 00000
19-Apr-2021
0000000000
000.00
Laboratory Services (Healthcare)
000000 00
00000 0000000
25-Feb-2021
0000000000
0000
Diagnostic Equipment
000000 00
0000000 00000
31-Jan-2020
0000000000
0000
Biotechnology
000000 00
00000 0000000
05-Sep-2019
000000000
0000
Diagnostic Equipment
00000000
Cell Targeting
28-Jan-2011
Merger/Acquisition
00.00
Biotechnology
To view OncoCyte’s complete investments and acquisitions history, request access »